#Senolytics

A breakthrough preclinical study has revealed that clearing “zombie cells” from spinal discs may dramatically reduce chronic low back pain, a condition that affects millions of people globally and remains common among Thais. Researchers from McGill University found that two drugs—o-Vanillin and RG-7112—can target and remove these senescent cells, leading not only to reduced pain and inflammation but even signs of tissue repair in damaged spinal discs. The findings, published in Science Advances, point to a transformative new treatment that addresses the root cause of back pain rather than just masking symptoms with painkillers or surgery source.

A preclinical study suggests that removing senescent or “zombie” cells from spinal discs may dramatically reduce chronic low back pain. Researchers at McGill University found that two drugs, o-Vanillin and RG-7112, can target and clear these cells, leading to reduced inflammation and signs of tissue repair in damaged spinal discs. The findings, published in Science Advances, point to a potential treatment that addresses the root causes of back pain rather than simply masking symptoms with painkillers or surgery.

A new study in Aging suggests senolytics—drugs once linked to anti-aging benefits—may slow Alzheimer’s disease progression. The findings are hopeful for millions affected by the condition, and they come as Thailand’s aging population grows. Experts urge cautious interpretation and careful clinical use as research continues.

Alzheimer’s disease involves amyloid-beta plaques in the brain, a factor associated with cognitive decline. The Thai audience especially understands the burden as families increasingly care for elderly relatives. The international study investigated six compounds known for anti-aging or cognitive-enhancing effects, including dasatinib and nintedanib, both considered senolytics. When tested on brain tissue from individuals with Alzheimer’s, these compounds appeared to selectively reduce pathological forms of brain enzymes linked to the plaques—without harming normal enzyme function.

In a groundbreaking new study published in the journal Aging, researchers have discovered that senolytics—compounds traditionally known for their anti-aging properties—might be able to slow the progression of Alzheimer’s disease. This finding offers a glimmer of hope to the millions impacted by Alzheimer’s, particularly as Thailand sees a growth in its aging population. The study’s promising results have sparked a renewed interest in senolytics, albeit with caution from the medical community about their application.